Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial
J. Sharman(Sarah Cannon), Franck Morschhauser(Centre Hospitalier Universitaire de Lille), Rosemary Harrup(University of Tasmania), Oscar Cazares, E. Ferrant(Hôpital Lyon Sud), R Marasca(University of Modena and Reggio Emilia), Michelle Boyer(Amgen (United States)), Stephen P. Mulligan(Royal North Shore Hospital), Stephen Opat(Monash Health), Luis Felipe Casado Montero(Complejo Hospitalario Universitario de Toledo), Yanwen Jiang(Amgen (United States)), Adalberto Ibatici(Ospedale Policlinico San Martino), Luca Laurenti(Agostino Gemelli University Polyclinic), Emma Clark(Roche (United Kingdom)), Paolo Sportoletti(University of Perugia), Maria Thadani-Mulero(Roche (United Kingdom)), Hyun Yong Jin(Scripps Research Institute), Weize Huang(Amgen (United States))
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
|Journal of Clinical Oncology|2018|313